Researchers performed a cross-sectional study that included multiple year pooled data (2003 to 2011) from the National Ambulatory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS Outpatient Department).
Proportion achieving target BP increased with use of triple combo pill vs usual care at 6 months.
Oral administration of BCX7353 at dose of 125 mg results in lower rate of attacks vs placebo.
Previous studies have suggested that analgesic medicine use may have a protective effect for patients with ovarian cancer.
First-line chemotherapy in combination with bevacizumab, compared with chemotherapy alone, may benefit patients with ovarian cancer and elevated neutrophil-to-lymphocyte ratios.
The recall affects approximately 470,000 units that include drugs packaged with 3 to 10 tablets per blister card. The blister packs were developed for use in hospitals, however some were sent to retail pharmacies and were likely dispensed for in-home use.
Investigators examined the relationship between the use of β-blockers and incidence of hypoglycemia and risk for mortality in hospitalized patients with diabetes.
AMA calls for greater manufacturer transparency in order to prepare for disasters, mitigate shortages.
The Company indicated that they will work towards an New Drug Application submission for the treatment in the second half of 2018.
Nonsteroidal anti-inflammatory drug use mediated a substantial amount of cardiovascular disease risk in osteoarthritis.
Prevalence of depression higher for adults reporting use of multiple meds with depression as side effect
No Additional Benefits With Vaginal Estradiol Tablets, Moisturizers for Postmenopausal Vulvovaginal SymptomsJune 14, 2018
Prescribed vaginal estradiol tablets and over-the-counter vaginal moisturizers may not be more effective than placebos for postmenopausal vulvovaginal symptoms.
The broad use of antidepressants among the general population may be linked to weight gain.
Two lots of naloxone hydrochloride injections, USP have been recalled by Hospira, Inc., due to concerns regarding the presence of particulates on the syringe plunger.
Burden of deaths up; most patients receiving opioid analgesics use immediate-release formulations
As this and previous research on dose increase strategies have produced inconsistent findings, the researchers recommended clinicians consider other responses to antidepressant treatment failure, at least for selective serotonin reuptake inhibitors.
Estimates of prescription medication use in children and adolescents showed an overall decrease in use of any medication from 1999 to 2014.
Migraine is highly prevalent in children and adolescents, affecting almost 10% of children between 5 and 15 years old and 30% of adolescents between 15 and 19 years old.
Payments correlated with prescribing opioids in 2014 may have influenced the increased prescription rates of 2015.
Anticholinergic drugs for depression, urologic conditions, or Parkinson disease are associated with potential dementia occurrences up to 20 years after drug exposure.
Relative decrease in buprenorphine-naloxone exposure after transition to unit-dose packaging
Intrathecal drug delivery systems and spinal cord stimulation have shown promise for the treatment of cancer pain in initial studies.
At discharge, 92.2% of patients received an opioid prescription; nearly 63% unused
For patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists significantly reduce mortality rates compared with dipeptidyl peptidase 4 inhibitors.
Patients with epilepsy have a greater risk of unnatural mortality than individuals without the disorder and should take greater precautions when taking certain medications.
Switching back to branded drugs is more likely in generic drug than authorized generic drugs.
Some allergic diseases associated with acid-suppressive, antibiotic intake in infants younger than 6 months old include food allergies, anaphylaxis, asthma, and allergic rhinitis.
The proposed pediatric indications are based on a 2018 Draft Guidance that supports extrapolating efficacy data of approved drugs to treat POS in adults to pediatric patients aged ≥4 years.
Increasing inhaled glucocorticoid doses at initial signs of exacerbating asthma may not be effective.
Recommendations for daily doses of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) resulted in protective drug concentrations for men and transgender women.